Comparison of Prilosec OTC® Versus Zegerid® for Gastric Acid Suppression
Information source: Procter and Gamble
Information obtained from ClinicalTrials.gov on February 12, 2009
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Normal Healthy Subject Population
Intervention: Zegerid® (Drug); Prilosec OTC® (Drug)
Phase: Phase 4
Status: Recruiting
Sponsored by: Procter and Gamble Official(s) and/or principal investigator(s):
Simon H Magowan, MD, Study Director, Affiliation: Procter and Gamble
Overall contact:
Simon H Magowan, MD, Phone: 513.622.4844, Email: magowan.sh@pg.com
Summary
The purpose of this study is to compare Prilosec OTC® and Zegerid® in their effects on
gastric acid suppression.
Clinical Details
Official title: Comparison of Prilosec OTC® Versus Zegerid® for Gastric Acid Suppression
Study design: Other, Randomized, Single Blind (Investigator), Crossover Assignment, Safety/Efficacy Study
Primary outcome: gastric pH
Eligibility
Minimum age: 18 Years.
Maximum age: 65 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Normal subjects who are 18-65 years of age;
- Non-childbearing potential females or those using birth control
Exclusion Criteria:
- History of significant GI disease
- Any significant medical illness
- History of hypersensitivity, allergy or intolerance to omeprazole or other proton pump
inhibitors;
- Currently using GI medications
- GI disorder or surgery leading to impaired drug absorption
Locations and Contacts
Simon H Magowan, MD, Phone: 513.622.4844, Email: magowan.sh@pg.com
Research Site, Oklahoma City, Oklahoma 73104, United States; Recruiting
Additional Information
Starting date: November 2008
Ending date: February 2009
Last updated: December 15, 2008
|
